By categorising these agents based on their functional synergy, we can observe a clear trend: they are no longer viewed merely as standalone lytic agents, but as powerful sensitisers and immunomodulators.
← all excerpts
Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook.
1
—
—